Literature DB >> 23371016

Letter in response to the recently published review: hyponatremia in cirrhosis and end-stage liver disease--treatment with the vasopressin v2-receptor antagonist tolvaptan.

A Abhyankar, S C Robson, E B Tapper, A Bonder.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23371016     DOI： 10.1007/s10620-013-2573-5

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN： 0163-2116            Impact factor:   3.199


× No keyword cloud information.
  5 in total

1.  Prognostic value of arterial pressure, endogenous vasoactive systems, and renal function in cirrhotic patients admitted to the hospital for the treatment of ascites.

Authors:  J Llach; P Ginès; V Arroyo; A Rimola; L Titó; S Badalamenti; W Jiménez; J Gaya; F Rivera; J Rodés
Journal:  Gastroenterology       Date:  1988-02       Impact factor: 22.682

2.  Hyponatremia in cirrhosis: Results of a patient population survey.

Authors:  Paolo Angeli; Florence Wong; Hugh Watson; Pere Ginès
Journal:  Hepatology       Date:  2006-12       Impact factor: 17.425

3.  Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia.

Authors:  Robert W Schrier; Peter Gross; Mihai Gheorghiade; Tomas Berl; Joseph G Verbalis; Frank S Czerwiec; Cesare Orlandi
Journal:  N Engl J Med       Date:  2006-11-14       Impact factor: 91.245

4.  Meta-analysis: the safety and efficacy of vaptans (tolvaptan, satavaptan and lixivaptan) in cirrhosis with ascites or hyponatraemia.

Authors:  E Dahl; L L Gluud; N Kimer; A Krag
Journal:  Aliment Pharmacol Ther       Date:  2012-08-21       Impact factor: 8.171

Review 5.  Hyponatremia in cirrhosis and end-stage liver disease: treatment with the vasopressin V₂-receptor antagonist tolvaptan.

Authors:  Paul Gaglio; Kwaku Marfo; Joseph Chiodo
Journal:  Dig Dis Sci       Date:  2012-06-26       Impact factor: 3.199
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.